Artificial intelligence (AI) and machine learning (ML) have potential to revolutionise cell and gene therapy (CGT), from patient recruitment to supply chain optimisation. Up to 90% of AI/ML models do not make it into production due to challenges in data handling and regulatory hurdles. CGT developers looking to adopt AI must ensure they are aware of these issues and address challenges relating to data availability, limitations in data access, algorithm validation and security.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
